Rochester Center for Behavioral Medicine Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2009
NCT01071044
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Rochester Center for Behavioral Medicine

Active Ingredients

Drugs in Phase 4 Trials (3)

guanfacine (tenex) (1 trial)

lisdexamfetamine (vyvanse) (1 trial)

solriamfetol (Sunosi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 4)

Cognitive Dysfunction (Phase 4)

Encephalomyelitis (Phase 4)

Fatigue (Phase 4)

Fatigue Syndrome, Chronic (Phase 4)

Myalgia (Phase 4)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3